Objective-To examine whether transfer from animal insulin to human insulin is associated with an increased risk of severe hypoglycaemia.
Introduction
Human insulins of recombinant DNA origin and semisynthetic human insulins manufactured from porcine insulin became available in Switzerland in 1983. They were not widely used until 1986, when two porcine preparations (Actrapid and Monotard Novo) were withdrawn and replaced by human preparations. Table I shows the annual increase in use of human insulin from 1984 to 1987 .
Impaired recognition of hypoglycaemia in diabetic patients transferred from animal insulin to human insulin was first reported from retrospective clinical surveys.'2 Reduced awareness of hypoglycaemia could lead to patients failing to take evasive action, with a consequent increased risk of progression to severe hypoglycaemia. The patients in these clinical series may, however, have developed impaired awareness of hypoglycaemia with time, irrespective of transfer to human insulin. 3 Subsequent work suggested that there could be a real difference in response to human and porcine insulin4 5; consequently, prospective randomised clinical trials have been advocated to clarify this issue.6 Such a trial would be a major undertaking, as the sample size requirements are considerable. For example, to detect a doubling of the risk of severe hypoglycaemia, assuming 5% of patients have one episode each year, about 1160 patients would have to be followed up for one year. ' Case-control studies require smaller sample sizes than prospective studies and can be completed in a shorter period of time.8 Case-control studies on this topic, however, are susceptible to bias if patients at high risk of hypoglycaemia were more likely to be transferred to human insulin. In Switzerland this was generally not the case because most patients were transferred to human insulin between 1984 and 1987 simply because porcine insulins became unavailable. We performed a case-control study of all patients with hypoglycaemia admitted to eight hospitals in the canton of Berne, Switzerland between 1984 and 1987.
Patients and methods

STUDY DESIGN AND DEFINITIONS
Cases and controls were identified from a computerised database (VESKA-Statistik9), which holds data on all patients admitted to 139 Swiss hospitals. The first visit of patients attending an outpatient clinic is also recorded. For each patient up to 10 diagnoses are coded according to the ICD ninth revision. Eight public hospitals in the canton of Berne (with 928 000 inhabitants in 1985) contribute to the VESKA-Statistik system, and all participated in our study. These included all three university hospitals (Inselspital, Tiefenauspital, and Zieglerspital), three regional hospitals (Interlaken, Langenthal, and Thun), and two district hospitals (Grosshochstetten and Niederbipp). These hospitals recorded 57-5% of all hospital admissions in the canton in 1987. Case admissions were defined as admissions for hypoglycaemia of insulin treated diabetic patients aged 16 to 90 years to one of the eight study hospitals from 1 January 1984 to 31 December 1987. Patients treated in an emergency ward and discharged on the same day were also included. The ICD (ninth revision) codes for "hypoglycaemic coma" (251-0) and "hypoglycaemia unspecified" (251-2) were used to identify case admissions. Although the code 250 2 ("diabetes with coma") applies to ketoacidotic or hyperosmolar coma, admissions for hypoglycaemic coma could be misclassified into this group. Therefore, hospital records for every admission with code 250 2 were also examined, and any misclassified admissions for hypoglycaemia were included.
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STATISTICAL ANALYSIS
The study design allowed for cases and controls to be included more than once, and the data may therefore be analysed by admissions or by patients. As controls were selected from those at risk of hypoglycaemia at the time of the hypoglycaemic episode of each case ("incidence density sampling"'2) the odds ratios obtained from a matched analysis will estimate the comparative incidences of hypoglycaemia as a ratio (the rate ratio).'2 '" From a statistical point of view a matched analysis based on admissions (not patients) is therefore appropriate, irrespective ofwhether the same patient was admitted more than once. It may be argued, however, that a few patients admitted several times will have undue weight in this analysis. Therefore, the data were analysed twice-once taking all admissions and once taking only the first admission of each patient as the unit of analysis. As the results of the two approaches were similar we present here only those results from analyses based on admissions. Univariate and multivariate relative rate estimates, probability values from X2 statistics, and 95% confidence intervals were calculated from matched analyses by using conditional logistic regression'4 (with EGRET software Ten admissions for hypoglycaemia (nine patients) and 19 control admissions (17 patients) were excluded from the analysis because of missing information on insulin preparation or blood glucose control or suicidal insulin overdose (one patient). Control admissions corresponding to excluded cases were retained in the data set and analysed in a stratum with an appropriate case by using the same matching criteria. Therefore, in the analysis 112 case admissions for hypoglycaemia (94 patients) were compared with 225 control admissions (182 patients), with a ratio of controls to cases ranging from one to four. Table III gives the reasons for admission of controls. (2-64%) in controls (n=56) Table V gives the characteristics ofhuman and animal insulin treated hypoglycaemia admissions. Blood glucose control was comparable in the two groups. They were also similar with respect to previous episodes of severe hypoglycaemia, onset of diabetes, body mass index, and insulin dose. Duration of diabetes was shorter in those treated with human insulin, although this was no longer apparent when only the 43 (83%) of admissions in patients who had been transferred to human insulin were considered. There was a trend towards more severe episodes of hypoglycaemia with human insulin. Seventeen (33%) admissions treated with human insulin were admitted with coma complicated by seizure or pyramidal signs, as compared with 10 (17%) treated with animal insulin (p=0 079). There were no deaths among the patients treated with animal insulin and one death in the group treated with human insulin (this patient has been described in detail elsewhere2). tReference. In clinical practice the decision to change a patient's treatment to human insulin could be influenced by their previous experience of hypoglycaemia. If patients at increased risk of hypoglycaemia are more likely to have their treatment changed to human insulin this could lead to an apparent higher risk of hypoglycaemia in patients taking human insulin. In this study such selection bias is unlikely to have occurred. In the period investigated patients were generally transferred to human insulin purely because of the non-availability of their porcine preparation. The decision to change treatment was therefore not influenced by clinical criteria. The repeat prescriptions held by patients detailed the trade name of the insulin (for example, Actrapid or Monotard), and at some stage when the patients attended the pharmacy to collect their insulin they would be given the human rather than the porcine form. Clinical evaluation of the patients did not play a part in this process. This is reflected by the fact that the time when the patients were transferred to human insulin was often not known to their doctor. That selective transfer of high risk patients to human insulin did not occur is also supported by the finding that a history of hypoglycaemic coma was no commoner among those admitted for hypoglycaemia who had been taking human insulin than those admitted for hypoglycaemia who had been taking animal insulin. Because those admitted to hospital represent only a small proportion of all patients with severe hypoglycaemia," admission bias must also be considered. If patients taking human insulin were more likely to be admitted to hospital when they developed hypoglycaemia than patients taking animal insulin, and if the same was not true for presentation of controls at hospital for other conditions, then a spurious apparent association between human insulin and hypoglycaemia could be generated. As transfer to human insulin was generally not influenced by patient characteristics it is unlikely that the propensity ofpatients to be referred to hospital for hypoglycaemia was related to the insulin preparation used. Furthermore, if patients taking human insulin were more likely to be admitted for a given episode of hypoglycaemia then the average severity of hypoglycaemia should be less in those taking human insulin. In fact, the tendency was for the reverse, with those taking human insulin being admitted with.more severe hypoglycaemia. Admission bias does not therefore seem to provide an adequate explanation of the findings.
CLINICAL CHARACTERISTICS OF CASE AND CONTROL ADMISSIONS
. Corresponding values for haemoglobin Alc were 8-08% (1 34%) in cases (n= 17) and 8 47% (1-89%) in controls (n=52), and mean blood glucose concentration was 9-88 (3 69) mmol/I in cases (n=57) and 11F54 (3 95)mmol/I in controls (n= 117
ANALYSIS OF RISK FACTORS
The comparison with the Swiss Diabetic Association control group also yielded a significant association between use of human insulin and hypoglycaemia. This comparison is not susceptible to bias due to patients taking human insulin having a lesser tendency to present with the conditions of the controls than patients taking animal insulin.
The possibility that the increased risk associated with human insulin could be accounted for by confounding by other risk factors for hypoglycaemia was assessed through multivariate adjustment for these factors. Such adjustments increased the relative rate of hypoglycaemia associated with use of human insulin. It is therefore improbable that the limited ability of such multivariate methods to control for confounding'6"' could account for the findings. Other factors associated with the use of human insulin, which were not assessed in our study, could possibly account for the findings. Such factors would have to be important risk factors for hypoglycaemia and be strongly associated with human insulin use to explain the relative rate of severe hypoglycaemia of 3 0 for human insulin. It seems unlikely that such a factor was missed in this study. Also, it is difficult to see how this confounding could have arisen, given the apparent lack of bias in the selection of cases and controls. This case-control study confirms that strict blood glucose control with human insulin is a risk factor for severe hypoglycaemia. This result is similar to that obtained in the diabetes control and complications trial,2' in which the rate of severe hypoglycaemic reactions in the intensively treated group was 54-1/100 person years as compared with 17-4/100 person years in the control group. The resulting rate ratio of 3-1 is comparable with the adjusted value of 2 9 , which in the present study was associated with good glycaemic control.
Age at onset of diabetes was not significantly related to risk of hypoglycaemia, nor did cases have diabetes of longer duration than controls. Cases and controls were therefore matched for age and sex and, to some extent, also for duration and age at onset of diabetes. The high proportion of men and of patients with onset before age 30 among cases nevertheless suggests that, as previously shown,242' male patients and patients with insulin dependent diabetes are at increased risk of hypoglycaemia.
In conclusion, our study offers evidence that transfer to human insulin may increase the risk of severe hypoglycaemia. Patients' treatment should be changed only under a doctor's guidance, and not in the pharmacy because their porcine preparations have become unavailable. As human insulin in general has no advantages over highly purified animal insulins28 the costs and benefits of universal transfer to human insulin should be seriously considered.
